Bupropion does suppress appetite in many people, though it is not FDA-approved as a standalone weight loss medication. It is approved for treating major depressive disorder and preventing seasonal affective disorder, and a different formulation is approved for smoking cessation. Weight loss and reduced appetite are well-documented side effects, and the drug’s appetite-related properties have made it one of the few antidepressants associated with weight neutrality or modest weight loss rather than weight gain.
How Bupropion Affects Appetite
Bupropion works by blocking the reuptake of two brain chemicals: dopamine and norepinephrine. This increases the availability of both in the brain. Dopamine plays a central role in reward and motivation, including the drive to eat, while norepinephrine influences energy expenditure and arousal. By raising dopamine levels, bupropion appears to reduce the rewarding quality of food, which can dampen cravings and lower overall interest in eating.
Bupropion also stimulates a group of neurons in the hypothalamus (the brain’s appetite control center) that produce signals telling your body it’s full. These same neurons are the target of the combination weight loss drug Contrave, which pairs bupropion with naltrexone. In that combination, bupropion activates the satiety signal while naltrexone blocks a feedback loop that would otherwise weaken that signal over time, making the pair more effective than bupropion alone.
How Much Weight Loss to Expect
On its own, bupropion produces modest weight loss. In a clinical trial comparing two doses to placebo, patients taking 150 mg daily lost an average of 0.5 kg (about 1 pound), while those on 300 mg daily lost about 1.0 kg (roughly 2.2 pounds), compared to just 0.2 kg for placebo. These numbers come from a standard treatment period for depression, not a dedicated weight loss trial, so they reflect what happens as a side effect rather than a targeted intervention.
A large real-world analysis of antidepressant use found that most antidepressants cause weight gain of roughly 0.25 to 0.75 percent of body weight over time. Bupropion was the clear outlier: weight change was near zero. This is a meaningful distinction if you’re choosing between antidepressants, since medications like citalopram and others in the SSRI class are consistently linked to gradual weight gain. The weight loss associated with bupropion persists during both short-term and long-term treatment, unlike fluoxetine (Prozac), where weight loss tends to occur only in the first few months before reversing.
Reductions in waist circumference become significant after about 26 weeks of use, based on a meta-analysis of randomized controlled trials. Clinical studies on bupropion and weight have ranged from 8 weeks to two full years, and the trend is consistent: modest but real weight reduction compared to placebo, with longer treatment producing more noticeable changes in body composition.
Bupropion Combined With Naltrexone
The FDA-approved weight loss medication Contrave combines bupropion with naltrexone specifically because the two drugs complement each other’s effects on appetite. Bupropion activates the brain’s fullness signals, but those signals naturally trigger a feedback mechanism that dials them back down over time. Naltrexone blocks that feedback loop, allowing the appetite-suppressing effect to persist longer than it would with bupropion alone.
The combination also appears to influence the brain’s reward pathways, reducing the motivational pull of food. This dual action on both satiety and food reward is why Contrave produces meaningfully more weight loss than bupropion by itself. If your primary goal is weight management rather than treating depression, this combination is the form that has been studied and approved for that purpose.
What It Doesn’t Do
Despite its effects on appetite and dopamine-driven food reward, bupropion has not shown effectiveness as a treatment for binge eating disorder. A randomized trial in overweight women with binge eating disorder found that bupropion did not reduce the frequency of binge episodes, food cravings, or other eating disorder symptoms compared to placebo. Remission rates were 42 percent for bupropion and 27 percent for placebo, a difference that was not statistically significant. The one area where bupropion did outperform placebo was overall weight loss, consistent with its general appetite-suppressing effects, but the binge eating itself did not improve.
This matters because it highlights the difference between general appetite suppression and the complex, emotionally driven patterns of disordered eating. Bupropion can reduce everyday food cravings and help you eat less, but it does not address compulsive or binge-type eating behavior.
Important Safety Concerns
Bupropion is contraindicated in people with eating disorders, including anorexia nervosa and bulimia nervosa, due to an increased risk of seizures. This is one of the most important safety considerations for anyone thinking about bupropion’s appetite effects. The seizure risk is dose-dependent and can be elevated by factors like electrolyte imbalances, purging behaviors, and severely restricted food intake, all of which are common in eating disorders.
This contraindication means bupropion should not be used as an appetite suppressant by anyone with a current or past eating disorder. The seizure risk also rises with higher doses, alcohol use, and certain other medications, so the drug’s weight loss properties need to be weighed in the context of your full medical picture.
Why Bupropion Stands Out Among Antidepressants
For people who need an antidepressant and are concerned about weight gain, bupropion occupies a unique position. Nearly every other commonly prescribed antidepressant is associated with at least some weight gain over time. Bupropion is the only widely used option that consistently trends toward weight neutrality or slight weight loss across both short-term and long-term use. This makes it a practical choice when depression treatment and weight management are both priorities, even though the weight loss itself is modest and should not be considered the primary reason for taking the medication.